Holen Sie sich die Stockscreener-App
1.15
8.00%
-0.10
Vorhandelsmarkt:
1.19
0.04
+3.48%
Schlusskurs vom Vortag:
$1.25
Offen:
$1.23
24-Stunden-Volumen:
624.41K
Relative Volume:
1.03
Marktkapitalisierung:
$36.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.4137
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+0.88%
1M Leistung:
-39.79%
6M Leistung:
-82.14%
1J Leistung:
-85.99%
1-Tages-Spanne:
$1.15
$1.2596
1-Wochen-Bereich:
$1.09
$1.305
52-Wochen-Spanne:
$1.09
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.15 | 35.75M | 0 | -69.00M | -55.26M | -2.78 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World
Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance
Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus
Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus
Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus
Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks
Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World
(ACRV) Investment Analysis - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com
You might want to take a look at Acrivon Therapeutics Inc (ACRV) now - Sete News
Acrivon Therapeutics Inc (ACRV)’s stock decline to 1.44 per share - uspostnews.com
Major Shareholder Sells Millions in Acrivon Therapeutics Stock! - TipRanks
ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Acrivon Therapeutics (ACRV) Sees Surge in Interest Amid Key Deve - GuruFocus
KeyBanc Capital Markets initates Acrivon Therapeutics Inc (ACRV) rating to an Overweight - knoxdaily.com
Understanding ACRV stock ratios for better investment decisions - uspostnews.com
Acrivon Therapeutics Presents Findings on ACR-2316's Mechanisms of Tumor Cell Death at AACR Annual Meeting - Nasdaq
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire
Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? - TradingView
(ACRV) On The My Stocks Page - news.stocktradersdaily.com
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):